The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Epidemiology and Outcome of Glioblastoma
Open accessAbstract
Glioblastoma (GBM) is the most aggressive malignant primary brain tumor. With an incidence rate of 3.19 per 100,000 persons in the United States and a median age of 64 years, it is uncommon in children. The incidence is 1.6 times higher in males compared to females and 2.0 times higher in Caucasians compared to Africans and Afro-Americans, with lower incidence in Asians and American Indians. GBM is commonly located in the supratentorial region (frontal, temporal, parietal, and occipital lobes) and is rarely located in cerebellum. Genetic and environmental factors have been investigated in GBM. Risk factors include prior radiotherapy, decreased susceptibility to allergy, immune factors and immune genes, as well as some single nucleotide polymorphisms detected by genomic analysis. Use of anti-inflammatory medication has been found to be protective against GBM. Survival from GBM is poor; only few patients survive 2.5 years and less than 5% of patients survive 5 years following diagnosis. Survival rates for patients with GBM have shown no notable improvement in population statistics in the last three decades. Molecular epidemiology integrates molecular technology into epidemiological studies and outcomes. The future of the epidemiology of GBM will depend on multicenter studies generating large clinical data sets of genomic data potentially leading to further understanding of the roles of genes and environment in the development of this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., Hahn, W. C., Ligon, K. L., Louis, D. N., Brennan, C., et al. (2007) · Genes & Development · doi:10.1101/gad.1596707 · Cited by 2,316
Epidemiologic and Molecular Prognostic Review of Glioblastoma
Thakkar, J. P., Dolecek, T. A., Horbinski, C., Ostrom, Q. T., Lightner, D. D., Barnholtz-Sloan, J. S., & Villano, J. L. (2014) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0275 · Cited by 1,390
Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., Abacioglu, U., Tavelin, B., Lhermitte, B., Hegi, M. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70265-6 · Cited by 1,286
Genetic Pathways to Glioblastoma
Ohgaki, H., Dessen, P., Jourde, B., Horstmann, S., Nishikawa, T., Di Patre, P.-L., Burkhard, C., Schüler, D., Probst-Hensch, N. M., Maiorka, P. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1337 · Cited by 1,270
Glioblastoma stem-like cells give rise to tumour endothelium
Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K. E., Geber, A., Fligelman, B., Leversha, M., Brennan, C., & Tabar, V. (2010) · Nature · doi:10.1038/nature09624 · Cited by 1,203
The Molecular Basis of Turcot's Syndrome
Hamilton, S. R., Liu, B., Parsons, R. E., Papadopoulos, N., Jen, J., Powell, S. M., Krush, A. J., Berk, T., Cohen, Z., Tetu, B., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503303321302 · Cited by 1,133
The Definition of Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3002 · Cited by 1,132
Stummer, W., Reulen, H.-J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J.-C., Rohde, V., Oppel, F., Turowski, B., Woiciechowsky, C., et al. (2008) · Neurosurgery · doi:10.1227/01.neu.0000317304.31579.17 · Cited by 1,035
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas
Watanabe, T., Nobusawa, S., Kleihues, P., & Ohgaki, H. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.080958 · Cited by 1,027
Pollard, S. M., Yoshikawa, K., Clarke, I. D., Danovi, D., Stricker, S., Russell, R., Bayani, J., Head, R., Lee, M., Bernstein, M., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2009.03.014 · Cited by 1,025 · cited 1×
“There is experimental evidence that GBM contains a subpopulation of highly tumorigenic cells (GBM stem cells) from which recurrent GBM is thought to derive (29–31),and that GBM has the capacity to differentiate into multiple lineages of tumor genesis (29, 31, 32).”
BackgroundEpidemiology and molecular pathology of glioma
Schwartzbaum, J. A., Fisher, J. L., Aldape, K. D., & Wrensch, M. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0289 · Cited by 949
Long-term survival with glioblastoma multiforme
Krex, D., Klink, B., Hartmann, C., von Deimling, A., Pietsch, T., Simon, M., Sabel, M., Steinbach, J. P., Heese, O., Reifenberger, G., et al. (2007) · Brain · doi:10.1093/brain/awm204 · Cited by 887
Hartmann, C., Hentschel, B., Wick, W., Capper, D., Felsberg, J., Simon, M., Westphal, M., Schackert, G., Meyermann, R., Pietsch, T., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0781-z · Cited by 829
Watanabe, K., Tachibana, O., Sato, K., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (1996) · Brain Pathology · doi:10.1111/j.1750-3639.1996.tb00848.x · Cited by 740
Murat, A., Migliavacca, E., Gorlia, T., Lambiv, W. L., Shay, T., Hamou, M.-F., de Tribolet, N., Regli, L., Wick, W., Kouwenhoven, M. C. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.7164 · Cited by 721
Primary and secondary glioblastomas: From concept to clinical diagnosis
Kleihues, P., & Ohgaki, H. (1999) · Neuro-Oncology · doi:10.1093/neuonc/1.1.44 · Cited by 586
Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge
Sturm, D., Bender, S., Jones, D. T. W., Lichter, P., Grill, J., Becher, O., Hawkins, C., Majewski, J., Jones, C., Costello, J. F., et al. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3655 · Cited by 555
Brennan, C., Momota, H., Hambardzumyan, D., Ozawa, T., Tandon, A., Pedraza, A., & Holland, E. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007752 · Cited by 534
Malignant Glioma: Lessons from Genomics, Mouse Models, and Stem Cells
Chen, J., McKay, R. M., & Parada, L. F. (2012) · Cell · doi:10.1016/j.cell.2012.03.009 · Cited by 527
Improved survival time trends for glioblastoma using the SEER 17 population-based registries
Koshy, M., Villano, J. L., Dolecek, T. A., Howard, A., Mahmood, U., Chmura, S. J., Weichselbaum, R. R., & McCarthy, B. J. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0738-7 · Cited by 481
COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells
Fujita, M., Kohanbash, G., Fellows-Mayle, W., Hamilton, R. L., Komohara, Y., Decker, S. A., Ohlfest, J. R., & Okada, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3055 · Cited by 385
Fueyo, J., Alemany, R., Gomez-Manzano, C., Fuller, G. N., Khan, A., Conrad, C. A., Liu, T.-J., Jiang, H., Lemoine, M. G., Suzuki, K., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.9.652 · Cited by 350
Glioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 327
Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities
Reuss, D. E., Kratz, A., Sahm, F., Capper, D., Schrimpf, D., Koelsche, C., Hovestadt, V., Bewerunge-Hudler, M., Jones, D. T. W., Schittenhelm, J., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1454-8 · Cited by 280
A population‐based description of glioblastoma multiforme in Los Angeles County, 1974–1999
Chakrabarti, I., Cockburn, M., Cozen, W., Wang, Y., & Preston‐Martin, S. (2005) · Cancer · doi:10.1002/cncr.21539 · Cited by 199
Age–incidence patterns of primary CNS tumors in children, adolescents, and adults in England
Arora, R. S., Alston, R. D., Eden, T. O. B., Estlin, E. J., Moran, A., & Birch, J. M. (2009) · Neuro-Oncology · doi:10.1215/15228517-2008-097 · Cited by 181
Mobile phone use and risk of brain neoplasms and other cancers: prospective study
Benson, V. S., Pirie, K., Schüz, J., Reeves, G. K., Beral, V., Green, J., & Collaborators, F. T. M. W. S. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt072 · Cited by 179
Perry, A., Miller, C. R., Gujrati, M., Scheithauer, B. W., Zambrano, S. C., Jost, S. C., Raghavan, R., Qian, J., Cochran, E. J., Huse, J. T., et al. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00167.x · Cited by 178
Brain Tumor Stem Cells: Bringing Order to the Chaos of Brain Cancer
Dirks, P. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.6792 · Cited by 171
Loss of Heterozygosity on Chromosome 19 in Secondary Glioblastomas
Nakamura, M., Yang, F., Fujisawa, H., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.6.539 · Cited by 141
Khurana, V. G., Jain, S., Smee, R., Cook, R., Dobes, M., Shadbolt, B., Smith, S., & Dexter, M. A. J. (2011) · Surgical Neurology International · doi:10.4103/2152-7806.90696 · Cited by 134
Nonoccupational risk indicators of glioblastoma in adults
Hochberg, F. H., Toniolo, P. G., Cole, P. T., & Salcman, M. (1990) · Journal of Neuro-Oncology · doi:10.1007/bf00182087 · Cited by 128
Dillman, R. O., Duma, C., Schiltz, P. M., DePriest, C. B., Ellis, R. A., Okamoto, K., Beutel, L. D., de Leon, C., & Chico, S. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200409000-00009 · Cited by 122
Mobile phone use and incidence of glioma in the Nordic countries 1979–2008: consistency check
Deltour, I., Auvinen, A., Feychting, M., Johansen, C., Klaeboe, L., Sankila, R., & Schüz, J. (2012) · Epidemiology · doi:10.1097/ede.0b013e3182448295 · Cited by 105
Gousias, K., Markou, M., Voulgaris, S., Goussia, A. C., Voulgari, P. V., Bai, M. C.-W., Polyzoidis, K. S., Kyritsis, A. P., & Alamanos, Y. (2009) · Neuroepidemiology · doi:10.1159/000222090 · Cited by 81
Joseph, N. M., Phillips, J. J., Dahiya, S. M., Felicella, M. M., Tihan, T., Brat, D. J., & Perry, A. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.173 · Cited by 67
Comparison of Survival Between Cerebellar and Supratentorial Glioblastoma Patients
Jeswani, S. P., Nuño, M., Folkerts, V., Mukherjee, D. R., Black, K. L., & Patil, C. G. (2013) · Neurosurgery · doi:10.1227/01.neu.0000430288.85680.37 · Cited by 66
Single-nucleotide polymorphisms in selected cytokine genes and risk of adult glioma
Brenner, A. V., Butler, M. A., Wang, S., Ruder, A. M., Rothman, N., Schulte, P. A., Chanock, S. J., Fine, H. A., Linet, M. S., & Inskip, P. D. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm210 · Cited by 65
Associations of High-Grade Glioma With Glioma Risk Alleles and Histories of Allergy and Smoking
Lachance, D. H., Yang, P., Johnson, D. R., Decker, P. A., Kollmeyer, T. M., Mccoy, L. S., Rice, T., Xiao, Y., Ali‐Osman, F., Wang, F. M., et al. (2011) · American Journal of Epidemiology · doi:10.1093/aje/kwr124 · Cited by 58
Treatment of unresectable glioblastoma multiforme.
Nieder, C., Grosu, A., Astner, S. T., & Molls, M. (2005) · PubMed · Cited by 53
Association between the XRCC1 Polymorphisms and Glioma Risk: A Meta-Analysis of Case-Control Studies
Jiang, L., Fang, X., Bao, Y., Zhou, J., Shen, X., Ding, M., Chen, Y., Hu, G., & Lu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055597 · Cited by 31
Association between adult height, genetic susceptibility and risk of glioma
Kitahara, C. M., Wang, S., Melin, B. S., Wang, Z., Braganza, M. Z., Inskip, P. D., Albanes, D., Andersson, U., Freeman, L. E. B., Buring, J. E., et al. (2012) · International Journal of Epidemiology · doi:10.1093/ije/dys114 · Cited by 28
Early Genetic Changes Involved in Low-Grade Astrocytic Tumor Development
Arjona, D., REY, J. A., & Taylor, S. (2006) · Current Molecular Medicine · doi:10.2174/156652406778195017 · Cited by 18
Use of Selective Cyclooxygenase-2 Inhibitors, Other Analgesics, and Risk of Glioma
Seliger, C., Meier, C. R., Becker, C., Jick, S. S., Bogdahn, U., Hau, P., & Leitzmann, M. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149293 · Cited by 8
Cited by
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 271
Tumor-derived exosomes in the regulation of macrophage polarization
Baig, M. S., Roy, A., Rajpoot, S., Liu, D., Savai, R., Banerjee, S., Kawada, M., Faisal, S. M., Saluja, R., Saqib, U., et al. (2020) · Inflammation Research · doi:10.1007/s00011-020-01318-0 · Cited by 267
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Yang, J., Luly, K. M., & Green, J. J. (2023) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1853 · Cited by 40
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
Au, T. H., Willis, C., Reblin, M., Peters, K. B., Nghiemphu, P. L., Taylor, J. W., Colman, H., Cohen, A. L., Ormond, D. R., Chakravarti, A., et al. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06514-0 · Cited by 34
Metadata
- Authors
- Department of Neurosurgery, J. U. H. A. M. S., TAMIMI, A. F., JUWEID, M., & Department of Radiology and Nuclear Medicine, J. U. H. A. M. S.
- Venue
- Glioblastoma
- Publisher
- Codon Publications
- Published
- 2017-09-22
- Pages
- 143-153
- OpenAlex
- W2757935580
- Cited by
- 484
- References
- 51
- FWCI
- 90.97
- Type
- book chapter
- Language
- it
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.